Format

Send to

Choose Destination
Vaccine. 2008 Feb 6;26(6):739-42. doi: 10.1016/j.vaccine.2007.12.001. Epub 2007 Dec 26.

The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.

Author information

1
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand. pstehrgreen@att.net

Abstract

As part of safety monitoring during a group B meningococcal disease vaccination campaign in New Zealand, we examined the possible excess risk of vaccine-associated simple febrile seizures (SFS). We conducted a cohort analysis using data from active hospital-based surveillance in the South Auckland area and a national immunisation register. Based on analysis of approximately 63,000 doses, we found no statistically significant increase in SFS incidence within 1, 2, 4, or 7 days after vaccination for any/all doses administered to children aged 6 months through 4 years. We concluded that the vaccine is unlikely to induce a heightened risk of SFS.

PMID:
18187240
DOI:
10.1016/j.vaccine.2007.12.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center